Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
about
Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@ast
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@en
type
label
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@ast
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@en
prefLabel
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@ast
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@en
P2093
P2860
P31
P50
P921
P1433
P1476
Magnitude of the benefit of pr ...... ung cancer: systematic review.
@en
P2093
Hiroe Kayatani
Katsuyuki Hotta
Masahiro Tabata
Nagio Takigawa
Natasha Leighl
Rabab Mohamed Gaafar
Taizo Hirata
Toshio Kubo
P2860
P304
P356
10.1371/JOURNAL.PONE.0121211
P407
P5008
P577
2015-03-16T00:00:00Z